These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16139792)

  • 1. The minimal functional sequence of protamine.
    Liang JF; Yang VC; Vaynshteyn Y
    Biochem Biophys Res Commun; 2005 Oct; 336(2):653-9. PubMed ID: 16139792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for improving the functionality of an affinity bioreactor.
    Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
    Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neutralization of a very low molecular weight heparin fraction CY 222 by protamine. In vitro and in vivo study].
    Doutremepuich C; Bonini F; de Seze O; Toulemonde F; Bayrou B
    Therapie; 1986; 41(6):433-6. PubMed ID: 3810539
    [No Abstract]   [Full Text] [Related]  

  • 5. [In vitro and in vivo neutralisation of a low molecular weight heparin fraction CY 216 by protamine].
    Doutremepuich C; Bonini F; Masse A; Bousquet F; Bayrou B; Toulemonde F
    Ann Pharm Fr; 1986; 44(1):65-72. PubMed ID: 3777780
    [No Abstract]   [Full Text] [Related]  

  • 6. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization.
    Chang LC; Lee HF; Yang Z; Yang VC
    AAPS PharmSci; 2001; 3(3):E17. PubMed ID: 11741268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
    Chang LC; Lee HF; Chung MJ; Yang VC
    Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of aprotinin on heparin activities and heparin neutralization with protamine.
    Azougagh Oualane F; Toulemonde F; Doutremepuich F; Doutremepuich C
    Thromb Res; 1992 Oct; 68(2):185-93. PubMed ID: 1282276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of two schemes of administering the Russian protamine sulfate after extracorporeal circulation in cardiosurgical patients].
    Charnaia MA; Morozov IuA; Gladysheva VG; Isaeva AM
    Anesteziol Reanimatol; 2006; (5):31-3. PubMed ID: 17184058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A less toxic heparin antagonist--low molecular weight protamine.
    Liang JF; Zhen L; Chang LC; Yang VC
    Biochemistry (Mosc); 2003 Jan; 68(1):116-20. PubMed ID: 12693985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the complex formation of heparin with protamine by light scattering and analytical ultracentrifugation: implications for blood coagulation management.
    Maurer J; Haselbach S; Klein O; Baykut D; Vogel V; Mäntele W
    J Am Chem Soc; 2011 Feb; 133(4):1134-40. PubMed ID: 21186806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of regulating blood clotting with heparin and its antagonists on mast cells].
    Efimov VS; Rozkin MIa; Poberiĭ IA; Lindner DP
    Farmakol Toksikol; 1981; 44(1):80-5. PubMed ID: 7262304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated partial thromboplastin time-protamine dose relation in the presence and absence of heparin.
    Inagaki M; Goto K; Katayama H; Benson KT; Goto H; Arakawa K
    J Cardiothorac Anesth; 1989 Dec; 3(6):734-6. PubMed ID: 2521031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide.
    He H; Ye J; Liu E; Liang Q; Liu Q; Yang VC
    J Control Release; 2014 Nov; 193():63-73. PubMed ID: 24943246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
    Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
    Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human protamines and the developing spermatid: their structure, function, expression and relationship with male infertility.
    Aoki VW; Carrell DT
    Asian J Androl; 2003 Dec; 5(4):315-24. PubMed ID: 14695982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin, protamine, and ionized calcium in vitro and in vivo.
    Goto H; Kushihashi T; Benson KT; Kato H; Fox DK; Arakawa K
    Anesth Analg; 1985 Nov; 64(11):1081-4. PubMed ID: 3931505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Action of modified heparins on coagulation: in vitro and in vivo studies.
    Stemberger AW; Riedl A; Haas S; Breddin HK; Walenga JM; Blümel G
    Semin Thromb Hemost; 1991; 17 Suppl 1():80-4. PubMed ID: 1648792
    [No Abstract]   [Full Text] [Related]  

  • 20. Polycationic calix[8]arenes able to recognize and neutralize heparin.
    Mecca T; Consoli GM; Geraci C; La Spina R; Cunsolo F
    Org Biomol Chem; 2006 Oct; 4(20):3763-8. PubMed ID: 17024282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.